Claro Advisors LLC Sells 376 Shares of Amgen Inc. (NASDAQ:AMGN)

Claro Advisors LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 14.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,146 shares of the medical research company’s stock after selling 376 shares during the quarter. Claro Advisors LLC’s holdings in Amgen were worth $618,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. OFI Invest Asset Management bought a new stake in shares of Amgen in the 3rd quarter valued at about $26,000. Briaud Financial Planning Inc acquired a new position in Amgen in the 3rd quarter valued at about $26,000. VisionPoint Advisory Group LLC acquired a new position in Amgen in the 2nd quarter valued at about $28,000. Strategic Investment Solutions Inc. IL acquired a new position in Amgen in the 1st quarter valued at about $28,000. Finally, Providence Capital Advisors LLC acquired a new position in Amgen in the 3rd quarter valued at about $30,000. 76.50% of the stock is owned by institutional investors.

Amgen Price Performance

AMGN stock opened at $284.32 on Monday. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The company has a fifty day moving average price of $289.21 and a 200-day moving average price of $281.03. The company has a market capitalization of $152.37 billion, a P/E ratio of 22.76, a PEG ratio of 2.69 and a beta of 0.58. The company has a debt-to-equity ratio of 10.14, a quick ratio of 1.13 and a current ratio of 1.65.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same quarter last year, the firm earned $4.09 earnings per share. Amgen’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, equities analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 72.06%.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AMGN. UBS Group decreased their price target on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating on the stock in a research note on Monday, January 29th. Royal Bank of Canada increased their target price on shares of Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. SVB Leerink lowered shares of Amgen from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $324.00 to $318.00 in a research report on Wednesday, February 7th. Morgan Stanley decreased their target price on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 7th. Finally, Daiwa Capital Markets upgraded shares of Amgen from a “neutral” rating to a “buy” rating and increased their target price for the stock from $264.00 to $320.00 in a research report on Thursday, December 21st. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $295.30.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.